P1.14-15 Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in Turkey
S. Kilickap,U. Demirci, F. Bugdayci,D. Tural, T. Korkmaz,S. Paydas,C. Yilmaz,H. Turna,A. Sezer,H. Yesil Cinkir,K. Okutur,M. Erman,Y. Eralp,D. Cabuk,A. Isikdogan,A. Demirkazik,A. Karaoglu,D. Yazilitas,F. Cay Senler,P.F. Yumuk,H. Coskun,I. Yildiz,I. Oztop,I. Beypinar,K. Aydin, M. Kaplan,N. Meydan, O.F. Olmez,O. Ozyilkan,S. Seber,C. Arslan, M.A. Sendur,I. Cicin JOURNAL OF THORACIC ONCOLOGY（2019）
关键词
ALK positive,ROS1 positive,Lorlatinib,Advanced stage lung cancer
AI 理解论文
溯源树
样例
